The role of bortezomib in the treatment of lymphoma

被引：28

作者：

Barr, Paul ^{[1
,2
]}

Fisher, Richard ^{[3
,4
]}

Friedberg, Jonathan ^{[3
,4
]}

机构：

[1] Case Western Reserve Univ, Case Comprehens Canc Ctr, Dept Hematol, Cleveland, OH 44106 USA

[2] Case Western Reserve Univ, Case Comprehens Canc Ctr, Dept Oncol, Cleveland, OH 44106 USA

[3] Univ Rochester, Sch Med, James P Wilmot Canc Ctr, Dept Hematol, Rochester, NY USA

[4] Univ Rochester, Sch Med, James P Wilmot Canc Ctr, Dept Oncol, Rochester, NY USA

来源：

CANCER INVESTIGATION | 2007年 / 25卷 / 08期

关键词：

lymphoma; chemotherapy; treatment;

D O I：

10.1080/07357900701579570

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Bortezomib is the first of the proteasome inhibitors to be used clinically. Among the various cancers susceptible to proteasome inhibition are the non-Hodgkin's lymphomas. Mantle cell lymphoma appears to be particularly sensitive, leading to the FDA approval of bortezomib in patients who have received at least one prior therapy. This demonstration of clinical efficacy has led to an explosion of research attempting to further understand the anti-tumor effect of proteasome inhibition and clinical investigations exploring bortezomib in combination with other agents. In this review, we will detail the clinical results and ongoing trials utilizing bortezomib in Hodgkin's and non-Hodgkin's lymphoma.

引用

页码：766 / 775

页数：10

共 86 条

[1]

Adams J, 1999, CANCER RES, V59, P2615

[2] The proteasome: A suitable antineoplastic target [J].